

**Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050**  
**Peds Open Studies**

**Registry**

- COG-ACCRN07 Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN) <http://clinicaltrials.gov/ct2/show/NCT00799253> [Albert Kheradpour, MD](#)
- COG-APEC14B1 Project: EveryChild - A Registry, Eligibility Screening, Biology and Outcome Study <https://clinicaltrials.gov/ct2/show/NCT02402244> [Albert Kheradpour, MD](#)

**CNS**

- COG-ACNS02B3 A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens <http://clinicaltrials.gov/ct2/show/NCT00919750> [Albert Kheradpour, MD](#)
- COG-ACNS0332 Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients <https://clinicaltrials.gov/ct2/show/NCT00392327> [Albert Kheradpour, MD](#)  
**ONLY Stratum A & B are OPEN to enrollment**
- COG-ACNS0831 Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years <http://www.clinicaltrials.gov/ct2/show/NCT01096368> [Albert Kheradpour, MD](#)

**Ewing's Sarcoma**

- COG-AEWS07B1 A Children's Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens (At Initial Diagnosis) <http://clinicaltrials.gov/ct2/show/NCT00899990> [Albert Kheradpour, MD](#)
- COG-AEWS1221 Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma <https://clinicaltrials.gov/ct2/show/NCT02306161> [Albert Kheradpour, MD](#)

**Germ Cell**

- COG-A031102 A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors <https://clinicaltrials.gov/ct2/show/NCT02375204> [Albert Kheradpour, MD](#)

**Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050**  
**Peds Open Studies**

**Hodgkin's Lymphoma**

COG-AHOD1331      A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents [Albert Kheradpour, MD](mailto:Albert.Kheradpour@stjude.org)  
<https://clinicaltrials.gov/ct2/show/NCT02166463>

**Kidney**

COG-AREN03B2      Renal Tumors Classification, Biology and Banking Study [Albert Kheradpour, MD](mailto:Albert.Kheradpour@stjude.org)  
<http://clinicaltrials.gov/ct2/show/NCT00898365>

**Leukemia**

COG-AALL05B1      A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens [Albert Kheradpour, MD](mailto:Albert.Kheradpour@stjude.org)  
<http://clinicaltrials.gov/ct2/show/NCT00897325>

COG-AALL08B1      Classification of Newly Diagnosed Acute Lymphoblastic Leukemia [Albert Kheradpour, MD](mailto:Albert.Kheradpour@stjude.org)  
<http://www.clinicaltrials.gov/ct2/show/NCT01142427>

COG-AALL0932      Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or localized B-Lineage Lymphoblastic Lymphoma (B-LLy) [Albert Kheradpour, MD](mailto:Albert.Kheradpour@stjude.org)  
<https://clinicaltrials.gov/ct2/show/NCT01190930>  
**Low Risk Arms C & M are CLOSED to enrollment**  
**Average Risk Post-Induction / Pre-Maintenance is CLOSED to enrollment**

COG-AALL1131      A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Testing Clofarabine (IND #73789, NSC #606869) in the Very High Risk Stratum [Albert Kheradpour, MD](mailto:Albert.Kheradpour@stjude.org)  
<http://clinicaltrials.gov/ct2/show/NCT01406756>  
**Stratum Very High Risk-Arm 2 is CLOSED to enrollment**

COG-AALL1231      A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy) [Albert Kheradpour, MD](mailto:Albert.Kheradpour@stjude.org)  
<https://clinicaltrials.gov/ct2/show/NCT02112916>

COG-AALL1331      Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) [Albert Kheradpour, MD](mailto:Albert.Kheradpour@stjude.org)  
<https://clinicaltrials.gov/ct2/show/NCT02101853>

COG-AALL1521      A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia [Albert Kheradpour, MD](mailto:Albert.Kheradpour@stjude.org)  
<https://clinicaltrials.gov/ct2/show/NCT02723994>

**Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050**  
**Peds Open Studies**

**Leukemia – continued**

COG-AAML08B1	Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS) <a href="http://www.clinicaltrials.gov/ct2/show/NCT00959283">http://www.clinicaltrials.gov/ct2/show/NCT00959283</a>	<a href="#">Albert Kheradpour, MD</a>
CCG-AAML1031	A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND #114480; NSC #681239, NSC #724772) for Patients with High Allelic Ratio FLT3/ITD <a href="http://www.clinicaltrials.gov/ct2/show/NCT01371981">http://www.clinicaltrials.gov/ct2/show/NCT01371981</a> <b>ONLY Arm C (cohort 3) &amp; Arm D are OPEN to enrollment</b>	<a href="#">Albert Kheradpour, M.D.</a>
COG-AAML1331	A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All Trans-Retinoic Acid <a href="https://clinicaltrials.gov/ct2/show/NCT02339740">https://clinicaltrials.gov/ct2/show/NCT02339740</a>	<a href="#">Albert Kheradpour, MD</a>
COG-AAML1522	A Phase II, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid) in Pediatric Subjects From 1 to 18 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia <a href="https://clinicaltrials.gov/ct2/show/NCT02538965">https://clinicaltrials.gov/ct2/show/NCT02538965</a>	<a href="#">Albert Kheradpour, MD</a>
COG-AAML1531	Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome <a href="https://clinicaltrials.gov/ct2/show/NCT02521493">https://clinicaltrials.gov/ct2/show/NCT02521493</a>	<a href="#">Albert Kheradpour, MD</a>
COG-ACCL1333	A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) treated with Pegylated (PEG) L-asparaginase <a href="https://clinicaltrials.gov/ct2/show/NCT02369653">https://clinicaltrials.gov/ct2/show/NCT02369653</a>	<a href="#">Albert Kheradpour, MD</a>

**Liver**

COG-AHEP0731	Treatment of Children with All Stages of Hepatoblastoma <a href="http://clinicaltrials.gov/ct2/show/NCT00980460">http://clinicaltrials.gov/ct2/show/NCT00980460</a> <b>ONLY Stratum 1 and 4 are OPEN to enrollment</b>	<a href="#">Albert Kheradpour, MD</a>
--------------	--	---------------------------------------

**Lymphoma**

COG-ALTE11C1	Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma <a href="https://clinicaltrials.gov/ct2/show/NCT01793233">https://clinicaltrials.gov/ct2/show/NCT01793233</a>	<a href="#">Albert Kheradpour, MD</a>
COG-ADVL1621	A Phase I/II Study of MK-3475 (Pembrolizumab) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051) <a href="https://clinicaltrials.gov/ct2/show/NCT02332668">https://clinicaltrials.gov/ct2/show/NCT02332668</a>	<a href="#">Albert Kheradpour, MD</a>

**Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050**  
**Peds Open Studies**

**Neuroblastoma**

- |              |  |                                       |
|--------------|--|---------------------------------------|
| COG-ANBL00B1 | Neuroblastoma Biology Studies<br><a href="http://clinicaltrials.gov/ct2/show/NCT00904241">http://clinicaltrials.gov/ct2/show/NCT00904241</a>   | <a href="#">Albert Kheradpour, MD</a> |
| COG-ANBL1232 | Utilizing Response and Biology Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma<br><a href="http://clinicaltrials.gov/ct2/show/NCT02176967">http://clinicaltrials.gov/ct2/show/NCT02176967</a> | <a href="#">Albert Kheradpour, MD</a> |

**Osteosarcoma**

- |              |  |                                       |
|--------------|--|---------------------------------------|
| COG-AOST06B1 | A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens<br><a href="http://clinicaltrials.gov/ct2/show/NCT00899275">http://clinicaltrials.gov/ct2/show/NCT00899275</a>  | <a href="#">Albert Kheradpour, MD</a> |
| COG-AOST1321 | Phase II Study of Denosumab (IND #127430, NSC #744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma<br><a href="https://clinicaltrials.gov/ct2/show/NCT02470091">https://clinicaltrials.gov/ct2/show/NCT02470091</a><br><b>ONLY Stratum 3 is OPEN to enrollment</b> | <a href="#">Albert Kheradpour, MD</a> |

**Rhabdomyosarcoma**

- |           |  |                                       |
|-----------|--|---------------------------------------|
| COG-D9902 | A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol<br><a href="http://clinicaltrials.gov/ct2/show/NCT00919269">http://clinicaltrials.gov/ct2/show/NCT00919269</a> | <a href="#">Albert Kheradpour, MD</a> |
|-----------|--|---------------------------------------|

**Rhabdomyosarcoma continued**

- |              |  |                                       |
|--------------|--|---------------------------------------|
| COG-ARST1321 | Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC #737754, IND #118613)<br><a href="http://clinicaltrials.gov/ct2/show/NCT02180867">http://clinicaltrials.gov/ct2/show/NCT02180867</a><br><b>ONLY Stratum 1 – Regimen A &amp; B are OPEN to enrollment</b> | <a href="#">Albert Kheradpour, MD</a> |
|--------------|--|---------------------------------------|

**Solid Tumors**

- |              |  |                                       |
|--------------|--|---------------------------------------|
| COG-ABTR01B1 | A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors<br><a href="http://clinicaltrials.gov/ct2/show/NCT00898079">http://clinicaltrials.gov/ct2/show/NCT00898079</a>  | <a href="#">Albert Kheradpour, MD</a> |
| COG-ADVL1621 | A Phase I/II Study of MK-3475 (Pembrolizumab) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)<br><a href="https://clinicaltrials.gov/ct2/show/NCT02332668">https://clinicaltrials.gov/ct2/show/NCT02332668</a> | <a href="#">Albert Kheradpour, MD</a> |

**Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050**  
**Peds Open Studies**

**Stem Cell Transplant**

NMDP-10-CBA

A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications  
<http://www.clinicaltrials.gov/ct2/show/NCT01351545>

[Albert Kheradpour, MD](#)

NMDP-RESEARCH DATABASE

Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries  
<http://www.clinicaltrials.gov/ct2/show/NCT00495300>

[Albert Kheradpour, MD](#)

NMDP-SAMPLE REPOSITORY

Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries  
<http://www.clinicaltrials.gov/ct2/show/NCT00495300>

[Albert Kheradpour, MD](#)